Sabbagh is on record saying that if a P3 is required it will be under FDA and with U.S. sites.
Sabbagh is also record, until the article was changed, saying that Anavex would likely need at least P3 trial also for safety given the organ wide activation of S1R.
In this and any other respect I will trust Sabbagh over Georgejjl, but otherwise I'll stay sceptical on Sabbagh too as I do with any investment considerations.
Market Data 
Markets 
AI
